jie qian national heart center & fuwai hospitall ffr in diffuse multivessel disease
TRANSCRIPT
![Page 1: Jie Qian National Heart Center & FuWai Hospitall FFR in Diffuse Multivessel Disease](https://reader035.vdocuments.us/reader035/viewer/2022062720/56649f115503460f94c24945/html5/thumbnails/1.jpg)
Jie Qian
National Heart Center & FuWai Hospitall
FFR in Diffuse Multivessel Disease
![Page 2: Jie Qian National Heart Center & FuWai Hospitall FFR in Diffuse Multivessel Disease](https://reader035.vdocuments.us/reader035/viewer/2022062720/56649f115503460f94c24945/html5/thumbnails/2.jpg)
Different Patients with the same symptom : angina
IVUS –based or FFR –Based PCI ?
Angio-based PCI
![Page 3: Jie Qian National Heart Center & FuWai Hospitall FFR in Diffuse Multivessel Disease](https://reader035.vdocuments.us/reader035/viewer/2022062720/56649f115503460f94c24945/html5/thumbnails/3.jpg)
Why do we need functional evaluation ?
Limitations of coronary angiography
Limitations of noninvasive techniques
Cost issues ( Cost / Benefit )
![Page 4: Jie Qian National Heart Center & FuWai Hospitall FFR in Diffuse Multivessel Disease](https://reader035.vdocuments.us/reader035/viewer/2022062720/56649f115503460f94c24945/html5/thumbnails/4.jpg)
Limitations of Angiography :
“Lumengram”: Disconnection with function & physiology
![Page 5: Jie Qian National Heart Center & FuWai Hospitall FFR in Diffuse Multivessel Disease](https://reader035.vdocuments.us/reader035/viewer/2022062720/56649f115503460f94c24945/html5/thumbnails/5.jpg)
FAME study: (dis)congruence between QCA and FFRFAME study: (dis)congruence between QCA and FFR
Key paper: Tonino et al; JACC 2010; 55: 2816-2821
![Page 6: Jie Qian National Heart Center & FuWai Hospitall FFR in Diffuse Multivessel Disease](https://reader035.vdocuments.us/reader035/viewer/2022062720/56649f115503460f94c24945/html5/thumbnails/6.jpg)
“I do not stent lesions of 50-70%”You are under-treating 40% of your patients
“I always stent lesions of 50-70%”You are over-treating 60% of your patients
“I only stent lesions > 70%”You are still over-treating 20% of your patients
IVUS does not solve this problem !(Key publication: Kang, Park, et al: Circulation Cardiov Interv 2011; 4: 65-71)
![Page 7: Jie Qian National Heart Center & FuWai Hospitall FFR in Diffuse Multivessel Disease](https://reader035.vdocuments.us/reader035/viewer/2022062720/56649f115503460f94c24945/html5/thumbnails/7.jpg)
Limitations of noninvasive techniques
Often not performed
Can be inaccurate in multivessel disease
Generally “territory” specific, but not “vessel” specific
Can be “vessel” specific “ but not “lesion “ specific
![Page 8: Jie Qian National Heart Center & FuWai Hospitall FFR in Diffuse Multivessel Disease](https://reader035.vdocuments.us/reader035/viewer/2022062720/56649f115503460f94c24945/html5/thumbnails/8.jpg)
Limitations of noninvasive techniques
143 patients with angiographically significant 3-vessel disease ( > 70% diameter stenosis)
18
36 36
10
0
5
10
15
20
25
30
35
40
No Defect 1-Vesselpattern
2-Vesselpattern
3-Vesselpattern
Tallium Scan Findings %
Lima et al , J Am Cll Cardiol 2003; 42:63-70
![Page 9: Jie Qian National Heart Center & FuWai Hospitall FFR in Diffuse Multivessel Disease](https://reader035.vdocuments.us/reader035/viewer/2022062720/56649f115503460f94c24945/html5/thumbnails/9.jpg)
Stress
Rest
Infero-lateral inducible ischemia
75 yrs male,
Hyperlipidemia .Hypertension and diabetes
Typical chest pain on exerction despite optimal medical therapy .
![Page 10: Jie Qian National Heart Center & FuWai Hospitall FFR in Diffuse Multivessel Disease](https://reader035.vdocuments.us/reader035/viewer/2022062720/56649f115503460f94c24945/html5/thumbnails/10.jpg)
FFR= 0.82
Following stent implantation at prox LCX
FFR= 0.72FFR= 0.97
![Page 11: Jie Qian National Heart Center & FuWai Hospitall FFR in Diffuse Multivessel Disease](https://reader035.vdocuments.us/reader035/viewer/2022062720/56649f115503460f94c24945/html5/thumbnails/11.jpg)
Functional Evaluation is not mandatory for every patient :
![Page 12: Jie Qian National Heart Center & FuWai Hospitall FFR in Diffuse Multivessel Disease](https://reader035.vdocuments.us/reader035/viewer/2022062720/56649f115503460f94c24945/html5/thumbnails/12.jpg)
Intermediate Lesion :
Chest pain , without non invasive ischemic test
Simple functional evaluation would provide better management …
![Page 13: Jie Qian National Heart Center & FuWai Hospitall FFR in Diffuse Multivessel Disease](https://reader035.vdocuments.us/reader035/viewer/2022062720/56649f115503460f94c24945/html5/thumbnails/13.jpg)
The angio-guided approach : is it the optimal approach ?
![Page 14: Jie Qian National Heart Center & FuWai Hospitall FFR in Diffuse Multivessel Disease](https://reader035.vdocuments.us/reader035/viewer/2022062720/56649f115503460f94c24945/html5/thumbnails/14.jpg)
Anatomic ScoringFor Each Lesion Segment
– Location– Length– Calcification– Tortuosity– Bifurcation– Diffuse Disease– Occlusion– Thrombus
SYNTAX Score
SYNTAX Score = 18 SYNTAX Score = 41
![Page 15: Jie Qian National Heart Center & FuWai Hospitall FFR in Diffuse Multivessel Disease](https://reader035.vdocuments.us/reader035/viewer/2022062720/56649f115503460f94c24945/html5/thumbnails/15.jpg)
0 6 12
20
40
0
Months Since Allocation
Cu
mu
lati
ve E
ven
t R
ate
(%
)
TAXUS™ Express2™ Stent (n=181)CABG (n=171)
MACCE to 12 Months by SYNTAX Score™ TercileLow Scores (0-22) 3VD Subset
Calculated by core laboratory; ITT population
P=0.66*
17.3%
15.2%
Event Rate ± 1.5 SE, *Fisher exact testPresenter: See Glossary
![Page 16: Jie Qian National Heart Center & FuWai Hospitall FFR in Diffuse Multivessel Disease](https://reader035.vdocuments.us/reader035/viewer/2022062720/56649f115503460f94c24945/html5/thumbnails/16.jpg)
0 6 12
20
40
0
Months Since Allocation
Cu
mu
lati
ve E
ven
t R
ate
(%
)
TAXUS™ Express2™ Stent (n=207)CABG (n=208)
MACCE to 12 Months by SYNTAX Score™ TercileIntermediate Scores (23-32) 3VD Subset
P=0.02*
18.6%
10.0%
Calculated by core laboratory; ITT populationEvent Rate ± 1.5 SE, *Fisher exact testPresenter: See Glossary
![Page 17: Jie Qian National Heart Center & FuWai Hospitall FFR in Diffuse Multivessel Disease](https://reader035.vdocuments.us/reader035/viewer/2022062720/56649f115503460f94c24945/html5/thumbnails/17.jpg)
0 6 12
20
40
0
Months Since Allocation
Cu
mu
lati
ve E
ven
t R
ate
(%
)
TAXUS™ Express2™ Stent (n=155)CABG (n=166)
MACCE to 12 Months by SYNTAX Score™ TercileHigh Scores (33) 3VD Subset
P=0.002*
21.5%
8.8%
Calculated by core laboratory; ITT populationEvent Rate ± 1.5 SE, *Fisher exact testPresenter: See Glossary
![Page 18: Jie Qian National Heart Center & FuWai Hospitall FFR in Diffuse Multivessel Disease](https://reader035.vdocuments.us/reader035/viewer/2022062720/56649f115503460f94c24945/html5/thumbnails/18.jpg)
48% of patients received ≥5 stents
Max #14 stents!
Stent Number and Length Higher in the SYNTAX Trial
0
5
10
15
20
0 1 2 3 4 5 6 7 8 9 10 11 12 13 14
Pat
ien
ts (
%)
Total Number of Stents Implanted per Patient
Multivessel disease: 96.2%* 3-vessel disease: 90.8%Avg. stents per patient: 4.6 ± 2.3 Avg. stented length: 86.1 mm
*3VD+LM/3VD+LM/2VD+LM/1VD
![Page 19: Jie Qian National Heart Center & FuWai Hospitall FFR in Diffuse Multivessel Disease](https://reader035.vdocuments.us/reader035/viewer/2022062720/56649f115503460f94c24945/html5/thumbnails/19.jpg)
Linear Increase in MACCE by Number of Stentsin the SYNTAX Trial
0,00
0,05
0,10
0,15
0,20
0,25
0,30
12m
MA
CC
E in
TA
XU
S A
rm
1 2 3 4 5 6 7 8+Number of Stents Implanted
12m MACCE Probability
12m MACCE Rate
4.6 StentsSYNTAX Average
17.8%
1.5 Stents“Typical” RealWorld Average
1 stent5.6%
Avg. in pts with5-8+ stentsin SYNTAX19.6%
1 432 5 6 7 8
![Page 20: Jie Qian National Heart Center & FuWai Hospitall FFR in Diffuse Multivessel Disease](https://reader035.vdocuments.us/reader035/viewer/2022062720/56649f115503460f94c24945/html5/thumbnails/20.jpg)
Functional SYNTAX Score •497 patients , FFR-guided arm of FAME Study•2-3 vessel disease •Angio Syntax Score : Conventional fashion •Functional ( FFR) Syntax Score : counting only the lesions with FFR < 0.80
Angio SYNTAX Functional ( FFR ) SYNTAX
FFR reclassifies > 30% !Fearon WF et al , TCT-MD 2011
![Page 21: Jie Qian National Heart Center & FuWai Hospitall FFR in Diffuse Multivessel Disease](https://reader035.vdocuments.us/reader035/viewer/2022062720/56649f115503460f94c24945/html5/thumbnails/21.jpg)
Funtctional SYNTAX Score desciminates Risk of Death/MI and Risk of Total MACE
Death / MI Total MACE
Fearon WF et al , TCT-MD 2011
![Page 22: Jie Qian National Heart Center & FuWai Hospitall FFR in Diffuse Multivessel Disease](https://reader035.vdocuments.us/reader035/viewer/2022062720/56649f115503460f94c24945/html5/thumbnails/22.jpg)
Is it safe to defer treatment ?
![Page 23: Jie Qian National Heart Center & FuWai Hospitall FFR in Diffuse Multivessel Disease](https://reader035.vdocuments.us/reader035/viewer/2022062720/56649f115503460f94c24945/html5/thumbnails/23.jpg)
DEFER Study : 5-year Follow-up ( Death / MI )
![Page 24: Jie Qian National Heart Center & FuWai Hospitall FFR in Diffuse Multivessel Disease](https://reader035.vdocuments.us/reader035/viewer/2022062720/56649f115503460f94c24945/html5/thumbnails/24.jpg)
27
9
0
5
10
15
20
25
30
35
FFR < 0.75 FFR > 0.75
MA
CE
at
1 ye
ar
%
p<0.05
Chamuleau et al , AJC 2002;89:377-80
Risk of deferring PCI if FFR < 0.75
![Page 25: Jie Qian National Heart Center & FuWai Hospitall FFR in Diffuse Multivessel Disease](https://reader035.vdocuments.us/reader035/viewer/2022062720/56649f115503460f94c24945/html5/thumbnails/25.jpg)
FFR-Guided PCI in Multivessel Disease
137 patients , non-randomized
Wongpraparut et al , AJC 2005; 96:877-884
![Page 26: Jie Qian National Heart Center & FuWai Hospitall FFR in Diffuse Multivessel Disease](https://reader035.vdocuments.us/reader035/viewer/2022062720/56649f115503460f94c24945/html5/thumbnails/26.jpg)
Angiography-guided PCI FFR-guided PCI
Measure FFR in all indicated stenoses
Stent all indicated stenoses
Stent only those stenoses with FFR ≤ 0.80
Randomization
Indicate all stenoses ≥ 50% considered for stenting
Patient with stenoses ≥ 50% in at least 2 of the 3 major
epicardial vessels
1-year follow-up
FLOW CHART
![Page 27: Jie Qian National Heart Center & FuWai Hospitall FFR in Diffuse Multivessel Disease](https://reader035.vdocuments.us/reader035/viewer/2022062720/56649f115503460f94c24945/html5/thumbnails/27.jpg)
FAME study: PRIMARY ENDPOINT
Composite of death, myocardial infarction, or repeat revascularization (“MACE”) at 1 year
![Page 28: Jie Qian National Heart Center & FuWai Hospitall FFR in Diffuse Multivessel Disease](https://reader035.vdocuments.us/reader035/viewer/2022062720/56649f115503460f94c24945/html5/thumbnails/28.jpg)
ANGIO-group
N=496
FFR-group
N=509P-value
Events at 1 year, No (%)
Death, MI, CABG, or repeat-PCI 91 (18.4) 67 (13.2) 0.020.02
Death 15 (3.0) 9 (1.8) 0.190.19
Death or myocardial infarction 55 (11.1) 37 (7.3) 0.040.04
CABG or repeat PCI 47 (9.5) 33 (6.5) 0.080.08
Total no. of MACE 113 76 0.020.02
Myocardial infarction, specified
All myocardial infarctions 43 (8.7) 29 (5.7) 0.070.07
Small periprocedural CK-MB 3-5 x N 16 12
Other infarctions (“late or large”) 27 17
FAME study: Adverse Events at 1 year
![Page 29: Jie Qian National Heart Center & FuWai Hospitall FFR in Diffuse Multivessel Disease](https://reader035.vdocuments.us/reader035/viewer/2022062720/56649f115503460f94c24945/html5/thumbnails/29.jpg)
FFR-guided
30 days2.9% 90 days
3.8% 180 days4.9% 360 days
5.3%
Angio-guided
absolute difference in MACE-free survival
FAME study: Event-free Survival
![Page 30: Jie Qian National Heart Center & FuWai Hospitall FFR in Diffuse Multivessel Disease](https://reader035.vdocuments.us/reader035/viewer/2022062720/56649f115503460f94c24945/html5/thumbnails/30.jpg)
Adverse Events at 2 Years
Angio-Guidedn = 496
FFR- Guidedn = 509
P Value
Total no. of MACE 139 105
Individual Endpoints
Death 19 (3.8) 13 (2.6) 0.25
Myocardial Infarction 48 (9.7) 31 (6.1) 0.03
CABG or repeat PCI 61 (12.3) 53 (10.4) 0.35
Composite Endpoints
Death or Myocardial Infarction 63 (12.7) 43 (8.4) 0.03
Death, MI, CABG, or re-PCI 110 (22.2) 90 (17.7) 0.07
![Page 31: Jie Qian National Heart Center & FuWai Hospitall FFR in Diffuse Multivessel Disease](https://reader035.vdocuments.us/reader035/viewer/2022062720/56649f115503460f94c24945/html5/thumbnails/31.jpg)
FAME study: 2-year Event-free Survival FAME study: 2-year Event-free Survival
![Page 32: Jie Qian National Heart Center & FuWai Hospitall FFR in Diffuse Multivessel Disease](https://reader035.vdocuments.us/reader035/viewer/2022062720/56649f115503460f94c24945/html5/thumbnails/32.jpg)
![Page 33: Jie Qian National Heart Center & FuWai Hospitall FFR in Diffuse Multivessel Disease](https://reader035.vdocuments.us/reader035/viewer/2022062720/56649f115503460f94c24945/html5/thumbnails/33.jpg)
Stent length / Number of stent
&
restenosis – stent thrombosis
![Page 34: Jie Qian National Heart Center & FuWai Hospitall FFR in Diffuse Multivessel Disease](https://reader035.vdocuments.us/reader035/viewer/2022062720/56649f115503460f94c24945/html5/thumbnails/34.jpg)
5,3
8,5
17,4
0
5
10
15
20
< 20 20 ~ 40 > 40
%
P<0.001
Stent Length is Independent Predictor of Restenosis.Lee CW et al. Am J Cardiol 2006;97:506-511
mm
![Page 35: Jie Qian National Heart Center & FuWai Hospitall FFR in Diffuse Multivessel Disease](https://reader035.vdocuments.us/reader035/viewer/2022062720/56649f115503460f94c24945/html5/thumbnails/35.jpg)
Non-Q-Wave MI Data from DES studies suggest Non-Q-Wave MI rates increase as total stented length increases.
TAXUS VMultiplestents7.3
1,5 0,81,9
2,73,4
4,7 4,6 4,8
6,87,3
16,1
0
2
4
6
8
10
12
14
16
18
TAXUS II RAVEL SIRIUS TAXUSIV
E-SIRIUS REALITYCYPHER
REALITYTAXUS
TAXUS V TAXUSVI
TAXUS VMultiplestents
WHCMultiplestents
15 mm Mean Stent length ( mm) 65 mm
Non
Q w
ave M
I
25mm 30mm 40 mm
TAXUS stent
Cyphert stent
![Page 36: Jie Qian National Heart Center & FuWai Hospitall FFR in Diffuse Multivessel Disease](https://reader035.vdocuments.us/reader035/viewer/2022062720/56649f115503460f94c24945/html5/thumbnails/36.jpg)
Full Metal Jacket.Ielasi, Colombo et al. Ital J Inv Cardiol 2009; 3 Suppl: 111
• 658 full metal jacket lesions (≥60mm) in 617 patients.
• 33% DM, 33 had prior PCI, 33% CTO.• 39 months mean follow up (2 yr in 91% pts).• Mortality 7.3%• MI during follow up: 3.5%• TLR: 23.4%• Stent thrombosis (Def or Probable): 2.6% (10/17
while on DAP).
![Page 37: Jie Qian National Heart Center & FuWai Hospitall FFR in Diffuse Multivessel Disease](https://reader035.vdocuments.us/reader035/viewer/2022062720/56649f115503460f94c24945/html5/thumbnails/37.jpg)
Longer Stents have more Thrombosis. Roy et al. AJC 2009; 803:801-5
• Independent Predictors of Cumulative ST.
• ISRS (OR 2.7, p<0.001)
• Number of stents (OR 1.7, p<0.001)• Clopridogrel Cessation (OR 1.7, p<0.001)• Diabetes (OR 1.5, p 0.2)• Renal Insufficiency (OR 1.4, p 0.4)
![Page 38: Jie Qian National Heart Center & FuWai Hospitall FFR in Diffuse Multivessel Disease](https://reader035.vdocuments.us/reader035/viewer/2022062720/56649f115503460f94c24945/html5/thumbnails/38.jpg)
Pressure wire assessment in MVD and diffuse disease is technically easy and offers more accurate functional evaluation of coronary stenoses.
Defering treatment of intermediate lesions when the FFR>0.80 seems safe and effective
Reducing the number and length of stents /vessel and or /patient is translated in less MACE on long term outcome
Conclusions
![Page 39: Jie Qian National Heart Center & FuWai Hospitall FFR in Diffuse Multivessel Disease](https://reader035.vdocuments.us/reader035/viewer/2022062720/56649f115503460f94c24945/html5/thumbnails/39.jpg)
THANKS!